I graduated with a PhD. in Psychiatry from the University of Edinburgh (Edinburgh, UK) in 2004 and subsequently undertook a fellowship at the National Institute on Drug Abuse (Baltimore, USA). During this fellowship I considered trait and state-specific effects on the neural substrates of reward processing in drug-dependent adults (i.e. cocaine and nicotine). In 2009 I moved to the Neuropsychiatric Genetics Group at Trinity College Dublin (Ireland) for a fellowship in imaging genetics. At Trinity my work focused on delineating neuro-endophenotypes in psychosis patients. I returned to the US in 2012 to collaborate with Dr. Diana Fishbein, first at the Transdisciplinary Science and Translational Prevention Program at RTI International (2012-2014) and then at newly formed the Center for Translational Research on Adversity, Neurodevelopment and Substance Abuse (C-TRANS) at the University of Maryland School of Medicine. In addition to my research work, I am also a working group member of the Brain Sciences Research Consortium Unit at the School of Medicine, which aims to support large-scale, multidisciplinary and translational studies on brain function. I also currently serve on the steering committee for the National Prevention Science Coalition, which promotes interdisciplinary, translational prevention science, evidence-based prevention and governmental adoption of a "prevention model" to reduce expenditure, in order to improve the chances for children to lead healthy, successful lives and for families and communities to thrive.
My primary research interests lie in delineating trait (e.g. genetic risk), state (e.g. acute drug effects) and situational (e.g. environmental) factors that mediate or moderate neurodevelopmental trajectories that underlie neuropsychiatric conditions. It is my belief that this work will: (1) inform improved models of disease etiology, (2) help us to better understand disease development, and (3) contribute to more efficacious prevention and treatment strategies, which are sensitive to differential patterns of responsivity and risk. To this end, my work has focused on using a combination of functional, structural and pharmacological magnetic resonance imaging and imaging genetics to address these concerns across a range of neuropsychiatric conditions, e.g. substance abuse and dependence (nicotine and cocaine), schizophrenia and depression.
Lab Techniques and Equipment:
Functional and structural magnetic resonance imaging
Rose, E.J., Morris, D.W., Fahey, C., Cannon, D., et al. (accepted manuscript). The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.
Mothersill, O., Morris, D.W., Kelly, S., Rose, E.J., et al (2014). Altered medial prefrontal activity during dynamic face processing in schizophrenia spectrum patients. Schizophrenia Research (epub ahead of print May 30 2014)
Kelly, S., Morris, D.W., Mothersill, O., Rose, E.J., Fahey, C., et al. (accepted manuscript). Genome-wide schizophrenia variant at MIR137 does not impact white matter microstructure in healthy participants. Neuroscience Letters
Rose, E.J., Salmeron, B., Ross, T.J., Schweitzer, J., Waltz, J., McClure, S. and Stein, E.A (2014). Temporal difference error prediction signal dysregulation in cocaine-dependence. Neuropsychopharmacology (epub ahead of print 1/29/2014) The ENIGMA Consortium (2014). Large scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 8(2), 153-182.
Mothersill, O., Morris, D.W., Kelly, S., Rose, E.J., Fahey, C., et al (2014). Effects of MIR137 on fronto-amygdala functional connectivity. NeuroImage, 90, 189-195.
Rose, E.J., Hargreaves, A., Greene, C., Jacobsen, S.J., Morris, D.W., et al. (2014) Effects of a genome wide supported schizophrenia risk variant at CNNM2 on brain structure and attributional style. British Journal of Psychiatry, 204(2), 115-121.
Rose, E.J., Morris, D.W., Hargreaves, A., Fahey, C., et al. (2013) Neural effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10504253. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 162B(6), 530-537.
Donohoe, G., Walters, J., Hargreaves, A., Rose E.J., Morris, D.W., Fahey, C., Bellini, S., Cummins, E., Giegling, I., Hartmann, A.M., Möller, H.J., Muglia, P., Owen, M.J., Gill, M., O'Donovan, M.C., Tropea, D., Rujescu, D., and Corvin, A. (2013). Neuropsychological Effects of the CSMD1 Genome-Wide Associated Schizophrenia Risk Variant rs10503253. Genes, Brain and Behavior, 12(2), 203-209.
Donohoe, G., Duignan, A., Hargreaves, A., Morris, D.W., Rose, E., Robertson, D., Cummings, E., Moore, S., Gill, M., and Corvin, A. (2012). Social cognition in bipolar disorder versus schizophrenia: comparability in mental state decoding deficits. Bipolar Disorders, 14(7), 734-738.
Rose, E.J., Ross, T.J., Salmeron, B., Lee, M., Shakleya, D.M., Huestis, M. and Stein, E.A. (2013). Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biological Psychiatry, 73(3), 280-288.
Rose, E.J. and Donohoe, G. (2013). Brain vs. behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia. Schizophrenia Bulletin, 39 (3), 518-526.
Mothersill, O.*, Kelly, S.*, Rose, E.J., and Donohoe, G (2012). The effects of psychosis risk variants on brain connectivity: A review. Frontiers in Psychiatry. (*equal author contribution).
The CHARGE Consortium (2012). Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nature Genetics, 44(5), 545-551.
The ENIGMA Consortium (2012). Common genetic polymorphisms contribute to the variation in human hippocampal and intracranial volume. Nature Genetics, 44(4), 552-561.
Rose, E.J., Greene, C., Kelly, S., Jacobsen, S.J., Morris, D.W., Robertson, I.H., O'Doherty, J., Newell, F.N., McGrath, J., Bokde, A., Garavan, H, Frodl, T., Gill, M., Corvin, A., and Donohoe, G. (2012). The NOS1 variant rs6490121 is associated with prefrontal function and grey matter density in healthy individuals. NeuroImage. 60(1), 614-622.
Rose, E.J., Morris, D.W., Fahey, C., Robertson, I.H., Greene, C., O'Doherty, J., Newell, F.N., Garavan, H., McGrath, J., Bokde, A., Gill, M., Corvin, A., and Donohoe, G. (2012). The effects of the neurogranin schizophrenia risk variant rs12807809 on brain structure and function. Twin Research and Human Genetics, 15(3), 296-303. (ENIGMA special issue)
Rose, E.J., Ross, T.J., Salmeron, B., Shakleya, D.M., Huestis, M., Lee. M., and Stein, E.A. (2012). Chronic exposure to nicotine is associated with reduced reward-related activity in the striatum but not the midbrain. Biological Psychiatry, 71(3), 206-213.
Hargreaves, A., Morris, D.W., Rose, E., Fahey, C., Tropea, D., Gill, M., Corvin, A., and Donohoe, G. (2012). ZNF804A and social cognition in patients with schizophrenia and healthy controls. Molecular Psychiatry, 17, 118-119.
Samson, A.C., Meisenzahl, E., Scheuerecker, J., Rose, E., Schoepf, V., Wiesmann, M., and Frodl, T. (2011) Brain activation predicts treatment improvement in patients with major depressive disorder. Journal of Psychiatric Research 45(9), 1214-1222.
Donohoe, G.,* Rose, E.J.,* Frodl, T., Morris, D.W., Spoletini, I., Cherubini, A., Adriano, F., Caltagirone, C., Bossu, P., Gill, M., Corvin, A.P., and Spalletta, G. (2011). ZNF804A risk allele is associated with relatively intact grey matter volume in patients with schizophrenia. NeuroImage, 54(3) 2131-2137. (*equal author contribution)
Donohoe, G., Walters, J., Morris, D.W., Da Costa, A., Rose, E., et al., (2011). A neuropsychological investigation of the genome-wide associated schizophrenia risk variant NRGN rs12807809. Schizophrenia Research, 125(2-3), 304-306.
Rose, E.J., Ross, T.J., Kurup, P.K., and Stein, E.A. (2010). Nicotine modulation of information processing is not limited to input (attention) but extends to output (intention). Psychopharmacology, 209(4) 291-302
Waltz, J.A., Schweitzer, J.B., Ross, T.J., Kurup, P.K., Salmeron, B., Rose, E.J., Gold, J.M., and Stein, E.A (2010). Abnormal responses to monetary outcome in the cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology, 35(12) 2427-2439.
Waltz, J.A., Schweitzer, J.B., Gold, J.M, Kurup, P.K., Ross, T.J., Salmeron, B., Rose, E.J., McClure, S.M., and Stein, E.A (2009). Patients with schizophrenia show a reduced BOLD response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology, 34, 1567-1577.
Rose, E.J. and Ebmeier, K.P. (2006). Pattern of impaired working memory during major depression. Journal of Affective Disorders, 90 (2-3), 149-161.
Rose, E.J., Simonotto, E., and Ebmeier, K.P. (2006). Limbic over activity in depression during preserved performance on the n-back task. NeuroImage, 29, 203-215
Rose, E.J., Simonotto, E., Spencer, E., and Ebmeier, K.P. (2006). The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology, 185 (3), 339-347.
Ebmeier, K., Rose, E., and Steele, D. (2006). Cognitive Impairment and fMRI in major depression. Neurotoxicity Research 10(2) 87-93.
Marshall, I., Simonotto, E., Deary, I.J., Maclullich, A., Ebmeier, K.P., Rose, E.J., Wardlaw, J.M., Goddard, N., Chappell, F.M. (2004). Repeatability of motor and working memory tasks in healthy older volunteers: assessment of functional MR imaging. Radiology, 233 (3), 868-877.
Faculty members: Update your contact information and create a profile.